Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the swiss HIV cohort study

Journal of Infectious Diseases

Volumn 203, Issue 6, 2011, Pages 791-797

  Scherrer, Alexandra U ^a   Von Wyl, Viktor ^a   Joos, Beda ^a   Klimkait, Thomas ^c   Bürgisser, Philippe ^d   Yerly, Sabine ^e   Böni, Jürg ^b   Ledergerber, Bruno ^a   Günthard, Huldrych F ^a   Battegay, M ^f   Bernasconi, E ^f   Boni J ^f   Bucher, H C ^f   Burgisser P ^f   Calmy, A ^f   Cattacin, S ^f   Cavassini, M ^f   Dubs, R ^f   Egger, M ^f   Elzi, L ^f   Fischer, M ^f   Flepp, M ^f   Fontana, A ^f   Francioli, P ^f   Furrer, H ^g   Fux, C A ^f   Gorgievski, M ^f   Gunthard H ^f   Hirsch, H H ^h   Hirschel, B ^h   Hosli I ^h   Kahlert, C ^h   Kaiser, L ^h   Karrer, U ^h   Kind, C ^h   Klimkait, T ^h   Ledergerber, B ^h   Martinetti, G ^h   Muller N ^h   Nadal, D ^h   Paccaud, F ^h   Pantaleo, G ^h   Rauch, A ^h   Regenass, S ^h   Rickenbach, M ^h   Rudin, C ^f   Schmid, P ^f   Schultze, D ^f   Schupbach J ^f   Speck, R ^f   De Tejada, B M ^f   Taffe, P ^f   Telenti, A ^f   Trkola, A ^f   Vernazza, P ^f   Weber, R ^f   Yerly, S ^f   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f SHCS ^*

^g Clinical and Laboratory Committee   (Switzerland)

^h Data Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ARGININE; ASPARAGINE; ASPARTIC ACID; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; GLUTAMIC ACID; GLUTAMINE; INDINAVIR; LAMIVUDINE; LEUCINE; LOPINAVIR; LYSINE; MARAVIROC; METHIONINE; NELFINAVIR; NEVIRAPINE; PHENYLALANINE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THREONINE; THYMIDINE; TRYPTOPHAN; TYROSINE; UNINDEXED DRUG; VALINE;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; SWITZERLAND; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; DIDANOSINE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MUTATION; RISK FACTORS; SWITZERLAND; TREATMENT OUTCOME;

EID: 79952334830     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq130     Document Type: Article

References (15)

1. Lodwick R, Costagliola D, Reiss P. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 170:410-419.
2. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44:2109-17. (Pubitemid 30484434)
3. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008; 10:67-84.
4. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-46. (Pubitemid 38328185)
5. Re MC, Borderi M, Monari P, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treated with antiretroviral drugs. Int J Antimicrob Agents 2001; 18:519-23. (Pubitemid 33152744)
6. Schmit JC, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998; 12:2007-15. (Pubitemid 28479277)
7. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-52. (Pubitemid 46147631)
8. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
9. Gallego O, d Mendoza C, Labarga P, et al. Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes. HIV Clin Trials 2003; 4:372-81.
10. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-90. (Pubitemid 47403067)
11. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort Study. Int J Epidemiol 2010; 39(5):1179-89.
12. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-45.
13. Winters MA, Coolley KL, Girard YA, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102:1769-75. (Pubitemid 28533822)
14. Zaccarelli M, Perno CF, Forbici F, et al. Q151M-mediated multi-nucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis 2004; 38:433-437. (Pubitemid 38200125)
15. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-17.